[ad_1]
©Reuters.
WALTHAM, Mass. – Revvity Inc. (NYSE: RVTY), a health science solutions provider, announced Signals ClinicalTM, a software-as-a-service (SaaS) platform aimed at enhancing clinical trial data management in the pharmaceutical, biotech, and medical fields. has been launched. and the contract research industry. The platform is designed to centralize clinical trial data to facilitate faster and more informed clinical decisions, thereby accelerating the delivery of new treatments to market.
The integration of Signals Clinical and Spotfire visual analytics is expected to improve the flexibility, customization, and scalability of data analysis in clinical research. Kevin Willoe, senior vice president and general manager of Revvity Signals Software, Inc., highlighted the platform’s potential to enhance data-driven decision-making and support the rapid introduction of new treatments.
Signals Clinical provides a central location for all clinical development data and provides self-service access for users. This centralization is aimed at providing a comprehensive view of patient safety, treatment efficacy, and trial progress, which could lead to faster insights and faster time-to-market for critical therapeutics. there is.
The platform also aims to streamline data preparation and provide strategic analyzes such as safety, efficacy, and cross-study analyses. The platform minimizes manual data processing, allowing organizations to focus on delivering critical clinical trial insights and fostering cross-functional collaboration.
Revvity Signals Software will introduce Signals Clinical at the 15th annual SCOPE conference, February 11-14 in Orlando, Florida. The company upholds his FAIR principles and offers customizable workflows for data management, clinical review, and research monitoring, as well as integrated collaboration tools that increase team efficiency.
Revvity has 2023 revenues of more than $2.7 billion, more than 11,000 employees, and operations around the world, serving customers in more than 190 countries. The company is known for its expertise in translational multi-omics technology, biomarker identification, and a variety of other health science fields.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.
[ad_2]
Source link
